financialmarketmovers.com
news-details
Health,Watchlist,healthcare stocks

6 HealthTech Stocks Trending Now FSPKF stock, RHHVF stock, ICPT stock, IOVA stock, RAIN stock, PLRX stock

Powered by healthtechmovers.com

According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist.  That staff here at financialmarketmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketMovers.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..

Fisher & Paykel Healthcare Corporation Limited, FSPKF
Recent FSPKF Stock Price: $16.36
Summary:
Fisher & Paykel Healthcare Corp Ltd is a designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The Company operates in four segments: New Zealand. Includes all activities controlled by entities or employees based in New Zealand, principally research and development, manufacturing, marketing, sales and distribution and administration. The research and development activity relates to New Zealand. The manufacturing activity principally relates to New Zealand, however the Mexico manufacturing activity is also included in this segment as the Mexico facility is managed by New Zealand-based employees. The sales and distribution activity principally relates to New Zealand, Latin America, Africa, the Middle East and other countries in Asia. Also included are sales made to countries within Europe and Asia-Pacific where the management of the sale is from New Zealand; North America. Includes all activities controlled by entities or employees based in the United States of America and Canada, principally sales, distribution and administration activities; Europe. Includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden and Turkey, principally sales, distribution and administration activities. These sales and distribution hubs also distribute product into neighboring European countries; and Asia-Pacific. Includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, principally sales, distribution and administration activities.

John Deakin-Bell analyst at Citigroup reiterates coverage on Fisher & Paykel Healthcare Corporation Limited (FSPKF) stock in the energy sector with a Hold rating and has set FSPKF's stock price target at $ 20.08.

TipRanks.com reports that Fisher & Paykel Healthcare Corporation Limited currently has 11 analysts offering 12-month price targets on FSPKF and the consensus is a Hold rating with an average stock price target of $16.15.  The most recent FSPKF stock price we have is $16.36 and we are not making any FSPKF forecasts at this time.

In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on FSPKF. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on FSPKF, please click here >>

Roche Holding AG, RHHVF
Recent RHHVF Stock Price: $318.764
Summary:
Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.

Keyur Parekh analyst at Goldman Sachs reiterates coverage on Roche Holding AG (RHHVF) stock in the energy sector with a Buy rating and has set RHHVF's stock price target at $ 435.63.

TipRanks.com reports that Roche Holding AG currently has 12 analysts offering 12-month price targets on RHHVF and the consensus is a Hold rating with an average stock price target of $375.91.  The most recent RHHVF stock price we have is $318.764 and we are not making any RHHVF forecasts at this time.

In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RHHVF. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on RHHVF, please click here >>

Intercept Pharma, ICPT
Recent ICPT Stock Price: $15.91
Summary:
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.

Navin Jacob analyst at UBS reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Hold rating and has set ICPT's stock price target at $ 20.

TipRanks.com reports that Intercept Pharma currently has 9 analysts offering 12-month price targets on ICPT and the consensus is a Moderate Buy rating with an average stock price target of $22.13.  The most recent ICPT stock price we have is $15.91 and we are not making any ICPT forecasts at this time.

In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on ICPT, please click here >>

Iovance Biotherapeutics, IOVA
Recent IOVA Stock Price: $7
Summary:
Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Geulah Livshits analyst at Chardan Capital reiterates coverage on Iovance Biotherapeutics (IOVA) stock in the energy sector with a Buy rating and has set IOVA's stock price target at $ 29.

TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets on IOVA and the consensus is a Moderate Buy rating with an average stock price target of $22.44.  The most recent IOVA stock price we have is $7 and we are not making any IOVA forecasts at this time.

In addition, TradingView issued a Buy rating for IOVA over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on IOVA, please click here >>

Rain Therapeutics, RAIN
Recent RAIN Stock Price: $9.85
Summary:
Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.

Sam Slutsky analyst at LifeSci Capital reiterates coverage on Rain Therapeutics (RAIN) stock in the energy sector with a Buy rating and has set RAIN's stock price target at $ 9.49.

TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets on RAIN and the consensus is a Strong Buy rating with an average stock price target of $17.07.  The most recent RAIN stock price we have is $9.85 and we are not making any RAIN forecasts at this time.

In addition, TradingView issued a Buy rating for RAIN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on RAIN, please click here >>

Pliant Therapeutics, PLRX
Recent PLRX Stock Price: $30.28
Summary:
Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.

Joseph Stringer analyst at Needham reiterates coverage on Pliant Therapeutics (PLRX) stock in the energy sector with a Buy rating and has set PLRX's stock price target at $ 45.

TipRanks.com reports that Pliant Therapeutics currently has 7 analysts offering 12-month price targets on PLRX and the consensus is a Strong Buy rating with an average stock price target of $48.43.  The most recent PLRX stock price we have is $30.28 and we are not making any PLRX forecasts at this time.

In addition, TradingView issued a Strong Buy rating for PLRX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on PLRX. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on PLRX, please click here >>



The editors at financialmarketmovers.com use a variety of research tools to generate our watchlists and research reports.  One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

FinancialMarketMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketMovers.com.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================